Sravathi AI Advances Cancer Drug Candidate in Collaboration with Mayo Clinic

Developing a drug candidate involves far more than generating a molecule. It requires identifying the right biological target, designing molecules against it, modelling their behaviour, and progressively narrowing down the most promising candidates for experimental validation. Our platform is designed to help bring these complex stages together and make the drug discovery process more efficient and data-driven.

This work was recently featured in The Times of India, one of India’s largest-read publications, and shared across eight of its leading editions, bringing this milestone to audiences across the country.

This achievement is part of a broader pipeline we are building. We now have nine assets in our pipeline, with four in advanced stages of discovery, giving us strong momentum as we enter the next phase of our journey.

For us, this is more than a milestone. It is an early demonstration of what AI-assisted drug discovery can make possible and how technology can help accelerate the journey from scientific insight towards potential new medicines.

We’re deeply grateful to everyone who has contributed to this effort. From our scientific and clinical teams to our collaborators and the many people working behind the scenes, this progress has been made possible through expertise, dedication, and collaboration.

We look forward to continuing this journey and pushing the boundaries of what is possible at the intersection of AI, biology, and drug discovery.

Read the full story in The Times of India: https://lnkd.in/dEyMfZj2